You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》康龍化成(03759.HK)收42.25元高上市價7% 每手賬面賺275元
阿思達克 11-28 16:23

康龍化成(北京)新藥技術股份(03759.HK)首日掛牌,股價高開10%報43.45元,最高見43.85元遇壓,午後曾回順至41.6元,全日收42.25元,較上市價39.5元,高2.75元或約7%,成交5,197萬股,涉資22.26億元。不計手續費,每手100股,賬面賺275元。

康龍化成是一家領先的全流程一體化醫藥研發服務平台,業務遍及全球,致力於協助客戶加速藥物創新。銀據弗若斯特沙利文資料,按2018年總收益計,康龍化是中國第二大醫藥研發服務平台及全球三大藥物發現服務供應商之一。

是次來港上市共發售1.165億股H股,而八名基石機構投資者合共認購3,172.63萬股H股;其中10%公開發售獲逾113倍超購,啟動回撥機制後佔比增至50%,申請一手中韱率100%,股份以招股範圍(34.5-39.5元)上限定價,料集資淨額43.44億元,主要用作擴展中國實驗室與生產設施的產能、建立研發生物製劑的醫藥研發服務平台、擴展臨床開發服務、潛在收購合同研發服務商及用於擴張美國及英國業務等。上市聯席保薦人分別為高盛、中信里昂證券及東方證券。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account